Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02922296 · ClinicalTrials.gov registry record
Glucose Metabolism in Sickle Cell Disease
A clinical trial of Sickle Cell Disease and Diabetes Mellitus, sponsored by University of Illinois at Chicago.
- Active
- Registry status
- 75
- Enrollment target
- 1
- Study location
NCT02922296 is a study of Sickle Cell Disease and Diabetes Mellitus that is active but no longer recruiting, run by University of Illinois at Chicago. The registered enrollment target is 75 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02922296, a study of Sickle Cell Disease and Diabetes Mellitus, is active but no longer recruiting, sponsored by University of Illinois at Chicago.
- ACTIVE NOT RECRUITING
- Registry status
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to better understand how the body handles sugars glucose and fats, such as cholesterol and triglycerides in sickle cell disease, and what puts certain persons at risk to develop diabetes. This understanding may help us to find new treatments to control blood sugar and prevent diabetes in people with and without sickle cell disease (SCD). In this research, DNA and RNA will be isolated from blood cells. DNA will be used to find genes that cause or protect from diabetes, high cholesterol and high triglyceride, and RNA will be used for studies designed to find out how genes are doing their job of eventually producing proteins.
Conditions Studied
Study Locations (1)
Illinois
- University of Illinois at Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2015-05-01 |
| Est. Completion | 2026-08-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02922296
The ClinicalTrials.gov registry entry for NCT02922296 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (74% lower). The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 0 interventions.
NCT02922296 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT02922296 about?
NCT02922296 is a clinical study titled "Glucose Metabolism in Sickle Cell Disease". The purpose of the study is to better understand how the body handles sugars glucose and fats, such as cholesterol and triglycerides in sickle cell disease, and what puts certain persons at risk to develop diabetes. This understanding may help us to find new treatments to control blood sugar and pre...
What is the current status of trial NCT02922296?
This trial is currently active not recruiting. The enrollment target is 75 participants. The study started on 2015-05-01. Estimated completion is 2026-08-01.
What conditions does trial NCT02922296 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Diabetes Mellitus.
Who is sponsoring clinical trial NCT02922296?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02922296 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Early Life Exposures Among Children With Sickle Cell Disease
RECRUITING · NA
-
Exercise in Child Health
RECRUITING · NA
-
Sickle Cell Children's Exercise Study (SuCCESs)
RECRUITING · NA
-
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
RECRUITING · Phase 1
-
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.